- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07223437
REVASC-PAD: Begrenset vaskulær trening for perifer arteriell sykdom - En gjennomførbarhetsstudie ved University of Tennessee Medical Center (REVASC-PAD)
The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).
The main aims of the study are:
- Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups
- Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms
- Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Tiffany Johnson, Study Coordinator
- Telefonnummer: +1865-305-4682
- E-post: thjohnson@utmck.edu
Studiesteder
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- Rekruttering
- University of Tennessee Medical Center
-
Hovedetterforsker:
- Morgan Randall, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years of age or older
- Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)
- Ankle-brachial index (ABI) between 0.4 and 0.9.
- Eligible referral to cardiovascular or pulmonary rehabilitation
- Prior revascularization permitted if symptoms are stable and other criteria are met
Exclusion Criteria:
- Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event
- Unstable angina
- Uncontrolled cardiac arrhythmias
- Symptomatic severe aortic stenosis or other significant valvular disease
- Decompensated symptomatic heart failure
- Acute pulmonary embolism or infarction
- Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)
- Acute myocarditis or pericarditis
- Acute thrombophlebitis
- Physical disability precluding safe or adequate exercise performance
- Significant electrolyte abnormalities
- Clinically significant tachyarrhythmias or bradyarrhythmias
- High-degree atrioventricular block
- Atrial fibrillation with uncontrolled ventricular response
- Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of >25 mmHg
- Known active aortic dissection
- Severe resting arterial hypertension (SBP>200mmHg or DBP >110 mmHg)
- Mental impairment preventing cooperation with study procedures
- Current pregnancy
- Moderate to severe peripheral neuropathy
- Open wounds or compromised skin near BFR cuff site
- Active DVT or thromboembolic event within the past year
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Blood Flow Restriction (BFR) Training
Participants perform supervised lower-body resistance training using pneumatic cuffs (Smart Cuff Pro or equivalent) applied to the proximal thighs. Cuffs are inflated to 60-80% of the participant's measured arterial occlusion pressure (AOP). Pressure is increased at Weeks 5 and 9 based on tolerance. Cuff inflation will not exceed 80% of limb occlusion pressure. Cuffs will be immediately deflated if participants' vitals suggest poor tolerance. |
All BFR resistance sessions will include two standardized lower-extremity exercises: seated calf raises and standing calf raises. Each session will follow this protocol:
|
|
Aktiv komparator: Low-Load Traditional Resistance Training (LL-RT)
Participants perform the same two calf exercises (seated and standing calf raises) without BFR cuffs. If participants demonstrate the ability to complete all prescribed repetitions without undue strain, planned load progressions of approximately 5-10% 1RM will be introduced at Weeks 5 and 9. Repetitions and sets will remain fixed to match the BFR protocol. |
Two resistance exercises (seated and standing calf raises) using the same repetition structure
|
|
Aktiv komparator: High-Load Traditional Resistance Training (HL-RT)
Participants in this group will perform seated and standing calf raises following a more conventional strength training model. Similar to the other groups, if participants can complete their prescribed workload without excessive strain, two planned load progressions (5-10% 1RM) will be applied at Weeks 5 and 9. Repetitions and sets will remain fixed to preserve consistency in training structure across groups. This group serves as a benchmark for conventional resistance training in clinical and musculoskeletal rehabilitation populations. |
Each session includes:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Walking Function
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
Change in walking distance measured by the Six-Minute Walk Test (6MWT) from baseline to end of intervention and 3-month follow-up visit. |
Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
|
Quality of Life (QoL) (1)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
Change in health-related quality of life as assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) from baseline to post-intervention and 3-month follow-up |
Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
|
Quality of Life (QoL) (2)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
Change in depressive symptoms as assessed by Patient Health Questionnaire-9 (PHQ-9) from baseline to post-intervention and 3-month follow-up |
Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
|
Quality of Life (QoL) (3)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
Change in self-reported walking function and symptom burden assessed by using REVASC-PAD Walking Questionnaire from baseline to post-intervention and 3-month follow-up |
Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Claudication Onset Time (COT) during 6MWT
Tidsramme: Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention
|
Time to onset of claudication symptoms during 6MWT at baseline, post-intervention, and 3-month follow-up |
Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention
|
|
Ratings of Perceived Exertion (RPE), Dyspnea, and Claudication Pain
Tidsramme: Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)
|
Session-based self-reported symptom ratings collected at each supervised exercise session from Visit 2 to end of intervention (approximately 8 to 12 weeks). These ratings assess exercise tolerance and symptom burden during blood flow restriction training. |
Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)
|
|
Adverse Event (AE) and Serious Adverse Event (SAE) Rates
Tidsramme: Baseline to 3-month follow-up
|
Number and rate of adverse events and serious adverse events occurring during the study period. |
Baseline to 3-month follow-up
|
|
Enrollment, Retention, and Adherence Rates
Tidsramme: Baseline to 3-month follow-up
|
Rates of successful enrollment, participant retention at post-intervention and 3-month follow-up, and adherence to prescribed exercise sessions |
Baseline to 3-month follow-up
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 5460
- Institutional Review Board (Annen identifikator: The University of Tennessee Health Science Center)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .